GlaxoSmithKline PLC Director/PDMR Shareholding (6058Z)
March 15 2017 - 12:07PM
UK Regulatory
TIDMGSK
RNS Number : 6058Z
GlaxoSmithKline PLC
15 March 2017
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
As previously announced, on 15 February 2017 the Company granted
conditional awards to certain Executive Directors and Persons
Discharging Managerial Responsibilities ('PDMR'). This announcement
relates to a PDMR who elected to participate in the GlaxoSmithKline
2009 Deferred Annual Bonus Plan ('DABP') in respect of his bonus on
a post-tax basis. The awards have been granted in accordance with
the rules of the DABP which was approved by shareholders on 20 May
2009.
Participants are required to defer 25% of any bonus earned into
Ordinary Shares or ADSs and may be eligible to choose to invest up
to an additional 25% (i.e. up to a maximum of 50%) pre-tax
(Deferred Bonus Award) and/or post-tax (Co-investment shares).
The Company will match the Deferred Bonus Award or Co-investment
shares up to one-for-one depending on the achievement of
performance targets (Matching Award). Details of the performance
measures will be confirmed later in the year following shareholder
approval of the Remuneration Policy at the Company's Annual General
Meeting.
The performance period for the awards is the three financial
years from 1 January 2017 to 31 December 2019.
The awards of deferred, co-investment and matching shares have
been granted as conditional awards over ADSs for US pre-tax
participants and as nil-cost options over Ordinary Shares for all
other participants.
The vesting date for these conditional awards will be the later
of the date, following the end of the three year performance
period, on which the Remuneration Committee determines the extent
to which the performance measures have been achieved, the third
anniversary of the Award Date or such other later date as
determined by the Remuneration Committee.
The amounts shown below are the maximum amounts payable
(exclusive of dividend reinvestment during the performance period).
The actual pay-out will be determined by performance over the
period. Progress against targets will be reported in the Company's
Annual Report yearly.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
==== ==============================================================================================
a) Name Mr B McNamara
==== ====================================== ======================================================
b) Position/status CEO, Consumer Healthcare
==== ====================================== ======================================================
c) Initial notification/ Initial Notification
amendment
==== ====================================== ======================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ======================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ======================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ====================================== ======================================================
b) Nature of the
transaction 1) Acquisition of post-tax Co-investment
ADSs (under the GlaxoSmithKline 2009 Deferred
Annual Bonus Plan).
2) Acquisition of a matching award conditional
award of ADSs (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject
to performance measures.
==== ====================================== ======================================================
c) Price(s) and volume(s) Price(s) Volume(s)
==== ====================================== ========================= =========================
$41.61 2,087
=========================================== ========================= =========================
$41.61 2,087
========================= =========================
d) Aggregated information
====
Aggregated volume
Price 4,174
$41.61
=========================================== ======================================================
e) Date of the transaction 2017-03-14
==== ====================================== ======================================================
f) Place of the transaction New York Stock Exchange (XNYS)
==== ====================================== ======================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDELFFDXFBBBE
(END) Dow Jones Newswires
March 15, 2017 13:07 ET (17:07 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
